The low uptake of the human papillomavirus (HPV) vaccine in the US and strategies to improve HPV vaccine coverage were highlighted in two studies presented at the Pediatric Academic Societies annual meeting (PAS 2019).
A 26-week regimen of liraglutide effectively improved glycaemic control in adolescents with type 2 diabetes (T2D) who had inadequate response to metformin, according to the results of the phase III Ellipse* trial presented as a poster at the recent Pediatric Academic Societies meeting (PAS 2019).
The use of text messaging as a reminder for the next human papillomavirus (HPV) vaccine dose may help increase the rates of HPV vaccine series completion, according to a study presented at PAS* 2019 Meeting.
Use of the novel quality improvement tool ‘Eat, Sleep, and Console’ (ESC) markedly reduced the length of hospitalization stay (LOS) and post-natal use of opiate medications in infants with in utero opioid exposure, according to data presented at PAS 2019.
Use of electronic vapour products (EVP), or vaping, has been associated with an increased likelihood of engaging in sexual and substance-use risk behaviours among US teenagers, according to data from the 2017 National Youth Risk Behaviour Survey presented at the Paediatric Academic Societies (PAS) 2019 Meeting.
Preterm infants with very low birth weight (VLBW) who were breastfed have significantly higher levels of metabolites important for brain growth and development in their brain tissue compared with formula-fed infants, suggesting that breastfed infants have improved cerebral metabolism at term-equivalent age, according to a study presented at the PAS 2019 Meeting.
Most of the vaccines routinely recommended in the US are safe with no evidence supporting a causal relationship between the vaccines and adverse events following immunization (AEFIs). Also, most of the AEFIs studied occurred rarely, according to a systematic review presented at the Pediatric Academic Societies (PAS) 2019 Meeting in Baltimore, Maryland, US.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.